Adial Pharmaceuticals, Inc.

ADIL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-1.1M
Depreciation & Amortization
Depreciation
Amortization $565
Stock-Based Compensation $205.4K
Net Cash from Operating Activities $-494.9K
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $35.1K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $390.0K
Net Change in Cash $-69.7K
Free Cash Flow
← Newer Page 2 of 2 Older →